OncoSec Summer Wrap-Up and Future Outlook

As the summer comes to an end, school begins, and the cool weather starts to set in, we wanted to share a recap of OncoSec’s milestones over the past few busy and exciting months.

In June, we announced a collaboration with University of California (UC) Davis School of Veterinary Medicine to test ImmunoPulse™ IL-12 as an immunotherapy in dogs with soft tissue sarcoma. We look forward to achieving a deeper understanding of our technology’s mechanism of action and validating key clinical biomarkers. As UC Davis is a pioneering institution in both human and veterinary medicine, they are an excellent collaborator in this pursuit.

That same month, we announced our first patient enrolled in a Phase II clinical trial of ImmunoPulse™ IL-12 in patients with squamous cell carcinoma of the head and neck (HNSCC). This study seeks to address one of the great unmet medical needs in oncology today: the number of patients who do not respond to anti-PD-1 treatment. We look forward to expanding the application of ImmunoPulse™ IL-12 beyond cutaneous cancer indications and anticipate that it will increase the number of patients who will respond to anti-PD-1 therapy.

In July, the OncoSec team journeyed from sunny San Diego to New York City’s Times Square to celebrate our listing to The Nasdaq Stock Market and ring the opening bell. This milestone served as a brief moment to celebrate how far we have come and reflect on the path ahead of us. We are doubling-down on our mission with laser-focus: deliver safer and more effective cancer treatments that can provide long-term benefits for patients.

In August, we enrolled the first patient into the Phase II Investigator Sponsored Trial to evaluate the combination of ImmunoPulse™ IL-12 and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab). This trial is led by the University of California, San Francisco (UCSF) to assess the anti-tumor activity, safety, and tolerability of this combination approach. We anticipate the data from this trial will provide further evidence that tumors need to be inflamed and possess tumor-infiltrating lymphocytes (TILs) in order for anti-PD-1 therapies to be most effective.

As we enter September, we were pleased to announce our advancements in electroporation and the future of catheter-based devices to perform minimally invasive intratumoral immunotherapy treatment at the First World Congress on Electroporation and Pulsed Electric Fields. We look forward to announcing upcoming milestones this month and what is shaping up to be an exciting fall.